Our pipeline covers both pharmaceutical and consumer product applications for disease treatment, disease interception and disease prevention.
Phase 1b/2a: MH002 - ulcerative colitis, ongoing expansion across gut inflammation.
Read MoreParkinson’s and metabolic diseases (co-development with IFF, formerly DuPont).
Ongoing program in spondylarthritis and autoimmune conditions.
By combining highly skilled scientists from different disciplines with an extensive in house technology platform, relevant market insights and sufficient financial means, MRM Health is in the unique position to exploit its expertise in gut physiology and microbiology for setting up a differentiating product development activity based on the use of live bacteria.
Contact us